Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASCT-I in Advanced Solid Tumors
NCT03034304Phase 1Terminated
- Sponsor
- HRYZ Biotech
- Start
- Feb 2017
- Primary completion
- Nov 2023
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of MASCT-I in solid tumor (advanced stage), urothelial carcinoma (UC), cholangiocarcinoma (CCA) and 2 more (6 arms), sponsored by HRYZ Biotech. Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 96 weeks. Started Feb 2017; status: terminated.
02
Drugs
MASCT-I
03
Conditions
solid tumor (advanced stage)urothelial carcinoma (UC)cholangiocarcinoma (CCA)soft tissue sarcoma (STS)osteosarcoma (OS)
Beyond the preview
Go deeper on NCT03034304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03034304.